先声药业:SIM0686临床试验获国家药监局批准

人民财讯
10 Apr

  人民财讯4月10日电,先声药业在港交所公告,公司自主研发的抗肿瘤候选药物FGFR2b抗体偶联药物(“ADC”)SIM0686已获得中国国家药监局签发的药物临床试验批准通知书,拟开展晚期实体瘤的临床试验。

(文章来源:人民财讯)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10